{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:12:35Z","timestamp":1793646755942,"version":"4.5.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3 DA044831"],"award-info":[{"award-number":["UH3 DA044831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jsat.2022.108801","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T17:32:58Z","timestamp":1652031178000},"page":"108801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis"],"prefix":"10.1016","volume":"141","author":[{"given":"Kim A.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canyon","family":"Foot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena A.","family":"Levander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Ponce","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"McIlveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108801_bb0005","series-title":"Scientific Software Development GmbH","year":"2020"},{"issue":"2","key":"10.1016\/j.jsat.2022.108801_bb0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qualitative Research in Psychology"},{"key":"10.1016\/j.jsat.2022.108801_bb0015","series-title":"Retention strategies for medications for addiction treatment in adults with opioid use disorder: A rapid evidence review","author":"Chan","year":"2020"},{"key":"10.1016\/j.jsat.2022.108801_bb0020","series-title":"Research design: Qualitative, quantitative, and mixed methods approaches","author":"Creswell","year":"2018"},{"issue":"1","key":"10.1016\/j.jsat.2022.108801_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt's like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on methadone maintenance treatment (MMT) patients' lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2022.108801_bb0035","article-title":"\u201cNo home to take methadone to\u201d: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston","volume":"108655","author":"Harris","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2022.108801_bb0045","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12913-019-4751-4","article-title":"Opioid use disorder and treatment: Challenges and opportunities","volume":"19","author":"Hoffman","year":"2019","journal-title":"BMC Health Services Research"},{"key":"10.1016\/j.jsat.2022.108801_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108219","article-title":"Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19","volume":"122","author":"Joseph","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"13","key":"10.1016\/j.jsat.2022.108801_bb0055","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states","volume":"322","author":"Joudrey","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jsat.2022.108801_bb0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jsat.2006.05.014","article-title":"A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model","volume":"31","author":"King","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"11","key":"10.1016\/j.jsat.2022.108801_bb5000","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2020.1624","article-title":"Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US","volume":"77","author":"Kleinman","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2022.108801_bb0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13722-021-00281-3","article-title":"Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19","author":"Levander","year":"2021","journal-title":"Addiction Science and Clinical Practice"},{"key":"10.1016\/j.jsat.2022.108801_bb0070","article-title":"COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership","volume":"1\u20137","author":"Levander","year":"2021","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2022.108801_bb0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States","volume":"46","author":"Lister","year":"2020","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2022.108801_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/1609406920937875","article-title":"Qualitative data collection in an era of social distancing","volume":"19","author":"Lobe","year":"2020","journal-title":"International Journal of Qualitative Methods"},{"issue":"9","key":"10.1016\/j.jsat.2022.108801_bb0085","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1176\/appi.ajp.2021.20101548","article-title":"Office-based methadone treatment for opioid use disorder and pharmacy dispensing: A scoping review","volume":"178","author":"McCarty","year":"2021","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2022.108801_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugpo.2018.08.006","article-title":"Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy","volume":"64","author":"McEachern","year":"2019","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2022.108801_bb0095","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000812","article-title":"Reduction in Oregon\u2019s medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication","author":"Mcilveen","year":"2021","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2022.108801_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/CXA.0000000000000015","article-title":"Large variation in provincial guidelines for urine drug screening during opioid agonist treatment in Canada","volume":"9","author":"Moss","year":"2018","journal-title":"The Canadian Journal of Addiction"},{"issue":"4","key":"10.1016\/j.jsat.2022.108801_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0740-5472(91)90044-B","article-title":"Medical maintenance: The treatment of chronic opiate dependence in general medical practice","volume":"8","author":"Novick","year":"1991","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2022.108801_bb0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/105504999305695","article-title":"A 12-year follow-up of a methadone medical maintenance program","volume":"8","author":"Schwartz","year":"1999","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2022.108801_bb0115","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"5","key":"10.1016\/j.jsat.2022.108801_bb0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/ADM.0000000000000770","article-title":"The impacts of COVID-19 on mental health, substance use, and overdose concerns of people who use drugs in rural communities","volume":"15","author":"Stack","year":"2021","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:57:01Z","timestamp":1760039821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"alternative-id":["S0740547222000836"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108801","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108801"}}